Project Grant R01DA064664
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $702K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Pittsburgh $700,254 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to examine how combined nicotine and opioid exposure alters the prefrontal cortex in opioid use disorder. The research addresses the gap between current OUD treatments and patient outcomes, particularly the role of nicotine dependence as a confounding factor. Between 80–90 percent of individuals with OUD smoke, yet smoking...
- The National Institute on Aging awarded The Rand Corporation $1.366 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct analyses of Medicare beneficiary access to medications for opioid use disorder and assess the impacts of state and federal policies on treatment disparities and health outcomes. The research examines barriers to access for the three FDA-approved medications to treat opioid use disorder: methadone, buprenorphine, and naltrexone. The study...
- The National Institute on Drug Abuse awarded Yale University $641,138 on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a study examining methadone dose-associated risks and outcomes in opioid use disorder treatment, with particular focus on aging adults. The research leverages a national cohort of approximately 54,000 patients receiving care in the Department of Veterans Affairs, derived from the Veterans Aging Cohorts Study's national cohort...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $945,601 under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 30, 2025, for the Personalized Methadone Treatment (PROMOTE) study implementing shared decision making in opioid treatment programs. The project adapts implementation facilitation—a bundle of preparation, implementation, and sustainment strategies—to support systematic shared decision making (SDM) implementation within opioid treatment...
- The National Institute on Drug Abuse awarded the University of Pittsburgh $198,164 on September 25, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research examining delta opioid receptor regulation of parvalbumin interneuron transmission and oxycodone-related behavior. The project investigates how delta opioid receptor signaling in parvalbumin-expressing GABAergic interneurons within the prefrontal cortex contributes to opioid use disorder symptoms,...
- The National Institute on Drug Abuse awarded The Trustees of Columbia University in the City of New York $1,555,130 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop quantitative evidence informing personalized, sequential medication-for-opioid-use-disorder (MOUD) treatment protocols. The research applies data fusion methodology to synthesize data from seven large MOUD trials conducted by the NIDA Clinical Trials Network, generating evidence-based...
- The National Institute on Drug Abuse awarded Johns Hopkins University $198,164 on October 17, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct research examining barriers to medications for opioid use disorder (MOUD) treatment for individuals transitioning from correctional facilities to community settings. The research employs a complex systems approach combining quantitative and qualitative methods. Specific aims include examining the structure and function...
- The National Institute on Drug Abuse awarded the University of Maryland, Baltimore $1,371,874 under the Drug Use and Addiction Research Programs (CFDA 93.279) on March 15, 2026, to investigate the impact of opioid use disorder on mitochondrial dysfunction among antiretroviral therapy-receiving aging people with HIV. The research addresses a gap in understanding how long-term antiretroviral therapy and opioid use disorder compound inflammaging—a low-grade chronic proinflammatory immune...
- The National Institute on Drug Abuse awarded New York University $103,607 on August 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct dissertation research on polysubstance use patterns and their associations with methadone maintenance treatment receipt and discontinuation among people who use drugs in New York State. The research uses a mixed-methods approach guided by the Social Ecological Model to identify latent polysubstance use patterns through urine...
- The National Institute on Drug Abuse awarded New York University $547,333 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a mixed-methods study identifying state-level implementation strategies for expanding access to extended take-home methadone doses in opioid treatment programs. The award funds a phased R61/R33 project examining how state agencies—including state opioid treatment authorities and Medicaid agencies—are facilitating adoption of...